These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3447451)

  • 1. Hippuric acid as a marker.
    Vanholder R; Schoots A; Cramers C; De Smet R; Van Landschoot N; Wizemann V; Botella J; Ringoir S
    Adv Exp Med Biol; 1987; 223():59-67. PubMed ID: 3447451
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia.
    Vanholder R; De Smet R; Schoots A; Ringoir S
    Nephron; 1988; 49(2):164-8. PubMed ID: 3380232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a double conjugate in uremic body fluids.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    FEBS Lett; 1981 Jul; 129(2):237-40. PubMed ID: 7286217
    [No Abstract]   [Full Text] [Related]  

  • 4. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
    Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
    Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma.
    Gulyassy PF; Jarrard E; Stanfel L
    Adv Exp Med Biol; 1987; 223():55-8. PubMed ID: 3128940
    [No Abstract]   [Full Text] [Related]  

  • 6. The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients.
    Cohen G; Raupachova J; Wimmer T; Deicher R; Hörl WH
    Nephrol Dial Transplant; 2008 Aug; 23(8):2512-9. PubMed ID: 18319358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry.
    Kikuchi K; Itoh Y; Tateoka R; Ezawa A; Murakami K; Niwa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(29):2997-3002. PubMed ID: 20870466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A; Myśliwiec M
    Nephrol Dial Transplant; 1993; 8(2):188. PubMed ID: 8384345
    [No Abstract]   [Full Text] [Related]  

  • 9. Are the classical markers sufficient to describe uremic solute accumulation in dialyzed patients? Hippurates reconsidered.
    Schoots AC; Dijkstra JB; Ringoir SM; Vanholder R; Cramers CA
    Clin Chem; 1988 Jun; 34(6):1022-9. PubMed ID: 3378319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbon Nanotube/Conducting Polymer Hybrid Nanofibers as Novel Organic Bioelectronic Interfaces for Efficient Removal of Protein-Bound Uremic Toxins.
    Yen SC; Liu ZW; Juang RS; Sahoo S; Huang CH; Chen P; Hsiao YS; Fang JT
    ACS Appl Mater Interfaces; 2019 Nov; 11(47):43843-43856. PubMed ID: 31663727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of toxic activity of blood in uremia].
    Shumakov VI; Gabriélian NI; Shcherbaneva OI; Dmitriev AA; Mogireva IA
    Ter Arkh; 1980; 52(4):62-4. PubMed ID: 7404340
    [No Abstract]   [Full Text] [Related]  

  • 12. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 14. Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid.
    Schoots AC; Verheggen TP; De Vries PM; Everaerts FM
    Clin Chem; 1990 Mar; 36(3):435-40. PubMed ID: 2311210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hemodialysis on serum concentrations of HPLC-analyzed accumulating solutes in uremia.
    Schoots AC; Peeters JA; Gerlag PG
    Nephron; 1989; 53(3):208-17. PubMed ID: 2507950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremic toxins.
    Ringoir S; Schoots A; Vanholder R
    Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
    Fagugli RM; De Smet R; Buoncristiani U; Lameire N; Vanholder R
    Am J Kidney Dis; 2002 Aug; 40(2):339-47. PubMed ID: 12148107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 19. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of urea and other uremic markers for quantification of dialysis efficacy.
    Vanholder RC; De Smet RV; Ringoir SM
    Clin Chem; 1992 Aug; 38(8 Pt 1):1429-36. PubMed ID: 1643710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.